I
Innate Pharma
Biotech & Life Sciences · Marseille, France · Founded 1999 · IPO 2015
Clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system MoreLess
Innate Pharma operates in the biopharmaceutical sector, focusing on the development of immunotherapy drugs for cancer treatment. The company specializes in creating NK cell engagers, which are designed to harness the body's natural immune response to target and destroy cancer cells. Innate Pharma collaborates with major pharmaceutical companies, such as Sanofi, to advance its drug candidates through clinical development. The business model involves research and development, followed by strategic partnerships and licensing agreements to commercialize its therapies. Revenue is generated through milestone payments and royalties from these collaborations. Innate Pharma primarily serves the oncology market, aiming to provide innovative solutions for unmet medical needs in cancer care. The company is publicly traded on Euronext Paris, which provides it with access to capital markets to fund its research initiatives. Keywords: biopharmaceutical, immunotherapy, cancer, NK cell engagers, oncology, drug development, partnerships, licensing, milestone payments, Euronext Paris.
Company overview
Innate Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 1999
- Headquarters
- Marseille, France
- Employees
- 176
- Open positions
- None listed
- Dealroom signal
- 63.9
Valuation & funding
Innate Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Aug 2026 | $33M | — | Bpifrance | ↗ |
| POST IPO EQUITY✓Other financing | Apr 2025 | $16M | — | Sanofi | ↗ |
| POST IPO EQUITY✓Other financing | Dec 2024 | $7.9M | — | The Institute for Follicular Lymphoma Innovation | ↗ |
| POST IPO SECONDARY✓Other financing | May 2022 | $75M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Oct 2019 | $69M | — | Undisclosed | — |
| IPO✓Exit | Jan 2015 | Undisclosed | — | ||
| POST IPO EQUITY✓Other financing | Jun 2014 | Redmile Group | — | ||
| POST IPO EQUITY✓Other financing | Nov 2013 | Redmile Group | — | ||
| SERIES C✓Equity / VC | Sep 2004 | Sofinnova Partners · Ardian · Auriga Partners · Akka Venture | — | ||
| SERIES B✓Equity / VC | Jan 2002 | Gimv · Sofinnova Partners · Ardian · Auriga Partners | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Innate Pharma website traffic
Latest recorded traffic for Innate Pharma is 9.2K monthly website visits, down 23.3% over the last three months. Innate Pharma's team declined 10.2% over the past year.
Comparisons
Innate Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Innate Pharma's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Innate Pharma has talent and traffic
team presence
In the news
Latest news about Innate Pharma
Recent press, funding announcements, and product moves mentioning Innate Pharma — open to read from the original sources.
Market sentiment
What the market is saying about Innate Pharma
An AI-synthesized read of the highest-engagement posts about Innate Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Innate Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.